Biomarin Pharmaceutical Inc

NASDAQ: BMRN
$66.04
+$0.03 (+0.0%)
Closing Price on November 5, 2024

BMRN Articles

With the three major stock indexes trading at or near all-time highs, many investors are scratching their heads about where to look for new investment ideas at a time when interest rates have become...
Despite the wearing down of hepatitis C drugs and the political climate targeting drug prices, this analyst sees stabilization and predictability in the base businesses of two key biotech leaders.
Shares of these five top companies offer tremendous upside to the Goldman Sachs price objective. While there is no guarantee they get there, moving just halfway to the targets would be outsized gains...
These five top stocks across five sectors offer tremendous upside to the Goldman Sachs price objectives. Moving just halfway to the targets would be outsized gains for investors.
The biotech team at SunTrust feel that it would not be a major surprise to see these six top companies post quarterly results that beat top-line Wall Street expectations.
The top analyst upgrades, downgrades and initiations seen on Wednesday included Aflac, Akamai, BioMarin, Caesars Entertainment, CBS, Crocs, GW Pharma, Medtronic, Netflix and Sirius XM.
The top analyst upgrades, downgrades and initiations seen on Friday included Activision Blizzard, BioMarin Pharmaceuticals, Ciena, Delta Air Lines, GlaxoSmithKline, Procter & Gamble, Regeneron...
Here is a preview of some of the world’s largest players in the health care sector reporting earnings this coming week.
The top analyst upgrades, downgrades and other research calls from Tuesday include Athenahealth, Illumina, Northrop Grumman, Square, Twitter and Yamana Gold.
Here, 24/7 Wall St. has included a calendar of a few of companies to watch for in the coming week and the rest of June.
Here 24/7 Wall St. has included a calendar of a few of companies to watch for in the coming week and the rest of June.
The top analyst upgrades, downgrades and other research calls from Friday include Starbucks, Splunk, PayPal, L Brands, Medtronic, Gap and Novartis.
Here 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates in May.
24/7 Wall St. has put together a preview of AbbVie, Eli Lilly and some of the other top pharma and biotech companies reporting their latest quarterly results in the coming week.
These four top Suntrust biotech picks for 2018 all have the potential for big upside moves if they do indeed exceed first-quarter expectations.